44.23
price up icon4.05%   1.72
after-market After Hours: 44.40 0.17 +0.38%
loading
Ptc Therapeutics Inc stock is traded at $44.23, with a volume of 1.54M. It is up +4.05% in the last 24 hours and up +3.46% over the past month. PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The Company views its operations and manages its business in one operating segment: life science.
See More
Previous Close:
$42.51
Open:
$44.29
24h Volume:
1.54M
Relative Volume:
1.46
Market Cap:
$3.96B
Revenue:
$900.66M
Net Income/Loss:
$-453.20M
P/E Ratio:
-7.4461
EPS:
-5.94
Net Cash Flow:
$-274.19M
1W Performance:
-11.45%
1M Performance:
+3.46%
6M Performance:
-0.11%
1Y Performance:
+42.45%
1-Day Range:
Value
$43.95
$46.03
1-Week Range:
Value
$35.95
$46.03
52-Week Range:
Value
$28.72
$58.38

Ptc Therapeutics Inc Stock (PTCT) Company Profile

Name
Name
Ptc Therapeutics Inc
Name
Phone
(908) 222-7000
Name
Address
500 WARREN CORPORATE CENTER DRIVE, WARREN, NJ
Name
Employee
939
Name
Twitter
@PTCBio
Name
Next Earnings Date
2024-11-07
Name
Latest SEC Filings
Name
PTCT's Discussions on Twitter

Compare PTCT with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
PTCT
Ptc Therapeutics Inc
44.23 3.96B 900.66M -453.20M -274.19M -5.94
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
424.99 128.84B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
527.78 65.38B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ARGX
Argen X Se Adr
549.65 39.67B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
251.15 33.82B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ONC
Beigene Ltd Adr
231.99 27.60B 3.81B -644.79M -669.77M -6.24

Ptc Therapeutics Inc Stock (PTCT) Upgrades & Downgrades

Date Action Analyst Rating Change
May-09-25 Upgrade BofA Securities Neutral → Buy
May-07-25 Upgrade Citigroup Sell → Neutral
Mar-11-25 Upgrade BofA Securities Underperform → Neutral
Mar-07-25 Initiated Scotiabank Sector Perform
Dec-13-24 Upgrade Morgan Stanley Equal-Weight → Overweight
Dec-03-24 Upgrade RBC Capital Mkts Sector Perform → Outperform
Oct-10-24 Resumed Raymond James Mkt Perform
Sep-04-24 Initiated Robert W. Baird Outperform
Aug-26-24 Resumed UBS Buy
May-20-24 Upgrade Raymond James Underperform → Mkt Perform
Dec-19-23 Downgrade Morgan Stanley Equal-Weight → Underweight
Dec-08-23 Initiated Wells Fargo Overweight
Oct-30-23 Upgrade Oppenheimer Perform → Outperform
Oct-27-23 Downgrade Citigroup Neutral → Sell
Oct-06-23 Downgrade Truist Buy → Hold
Sep-18-23 Downgrade Citigroup Buy → Neutral
Sep-15-23 Downgrade Raymond James Outperform → Underperform
Mar-17-23 Initiated SVB Securities Market Perform
Dec-14-22 Initiated Goldman Sell
Sep-12-22 Initiated Jefferies Buy
Sep-09-22 Initiated Morgan Stanley Equal-Weight
Sep-01-22 Initiated Citigroup Buy
Apr-04-22 Resumed Cantor Fitzgerald Overweight
Oct-18-21 Downgrade BofA Securities Neutral → Underperform
Apr-26-21 Resumed Credit Suisse Neutral
Mar-29-21 Upgrade RBC Capital Mkts Underperform → Sector Perform
Feb-12-21 Downgrade BofA Securities Buy → Neutral
Jan-05-21 Upgrade Citigroup Neutral → Buy
Nov-30-20 Downgrade RBC Capital Mkts Sector Perform → Underperform
Oct-30-20 Downgrade Citigroup Buy → Neutral
Oct-28-20 Initiated UBS Neutral
Oct-07-20 Upgrade JP Morgan Neutral → Overweight
Aug-25-20 Initiated Raymond James Outperform
Apr-09-20 Upgrade Citigroup Neutral → Buy
Feb-20-20 Downgrade Citigroup Buy → Neutral
Feb-20-20 Downgrade RBC Capital Mkts Outperform → Sector Perform
Nov-12-19 Initiated SunTrust Buy
May-13-19 Upgrade BofA/Merrill Neutral → Buy
Apr-11-19 Initiated Bernstein Outperform
Oct-03-18 Upgrade BofA/Merrill Underperform → Neutral
Oct-01-18 Initiated Cantor Fitzgerald Overweight
Jul-19-18 Initiated Credit Suisse Outperform
Jun-18-18 Upgrade RBC Capital Mkts Sector Perform → Outperform
Apr-04-18 Downgrade Barclays Equal Weight → Underweight
Jan-29-18 Resumed RBC Capital Mkts Sector Perform
Nov-16-17 Upgrade JP Morgan Underweight → Neutral
Oct-26-17 Downgrade BofA/Merrill Neutral → Underperform
Oct-09-17 Downgrade JP Morgan Neutral → Underweight
View All

Ptc Therapeutics Inc Stock (PTCT) Latest News

pulisher
10:40 AM

PTC Therapeutics, Inc. (PTCT): Among Billionaire David E. Shaw’s Small-Cap Stock Picks with Huge Upside Potential - Insider Monkey

10:40 AM
pulisher
08:38 AM

Driehaus Capital Management LLC Makes New $46.99 Million Investment in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat

08:38 AM
pulisher
05:14 AM

AQR Capital Management LLC Sells 32,230 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat

05:14 AM
pulisher
03:15 AM

William Blair Boosts Earnings Estimates for PTC Therapeutics - Defense World

03:15 AM
pulisher
03:12 AM

JPMorgan Chase & Co. Cuts PTC Therapeutics (NASDAQ:PTCT) Price Target to $67.00 - Defense World

03:12 AM
pulisher
02:27 AM

PTC Therapeutics (NASDAQ:PTCT) Upgraded at Citigroup - Defense World

02:27 AM
pulisher
12:42 PM

Tudor Investment Corp ET AL Increases Stock Position in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat

12:42 PM
pulisher
May 09, 2025

PTC Therapeutics, Inc. (PTCT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire

May 09, 2025
pulisher
May 09, 2025

Lost Money on PTC Therapeutics, Inc. (PTCT)? Contact Levi & Korsinsky Regarding an Ongoing Investigation - ACCESS Newswire

May 09, 2025
pulisher
May 09, 2025

Shareholders Who Lost Money on PTC Therapeutics, Inc. (PTCT) Should Contact Levi & Korsinsky About Securities Fraud InvestigationPTCT - ACCESS Newswire

May 09, 2025
pulisher
May 09, 2025

B of A Securities Upgrades PTC Therapeutics (PTCT) - Nasdaq

May 09, 2025
pulisher
May 09, 2025

PTC Therapeutics (NASDAQ:PTCT) Shares Gap Up Following Strong Earnings - MarketBeat

May 09, 2025
pulisher
May 09, 2025

Cantor Fitzgerald Cuts PTC Therapeutics (NASDAQ:PTCT) Price Target to $112.00 - MarketBeat

May 09, 2025
pulisher
May 09, 2025

BofA Upgrades PTC Therapeutics to Buy From Neutral, Adjusts Price Target to $68 From $55 - marketscreener.com

May 09, 2025
pulisher
May 09, 2025

PTC Therapeutics (NASDAQ:PTCT) Raised to Neutral at Citigroup - MarketBeat

May 09, 2025
pulisher
May 09, 2025

Baker BROS. Advisors LP Takes Position in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat

May 09, 2025
pulisher
May 08, 2025

PTC Therapeutics (PTCT) Receives Upgrade from BofA with New Price Target | PTCT Stock News - GuruFocus

May 08, 2025
pulisher
May 08, 2025

PTCT: Barclays Lowers Price Target for PTC Therapeutics to $42 | PTCT Stock News - GuruFocus

May 08, 2025
pulisher
May 08, 2025

ATTENTION PTCT SHAREHOLDERS: Investors who lost money on PTC Therapeutics, Inc. are urged to contact Levi & Korsinsky about an ongoing investigation - ACCESS Newswire

May 08, 2025
pulisher
May 08, 2025

PTC Therapeutics, Inc. (PTCT) Investors with Losses are Urged to Contact Levi & Korsinsky to Discuss Their Rights - ACCESS Newswire

May 08, 2025
pulisher
May 08, 2025

PTC Therapeutics, Inc. (NASDAQ:PTCT) Q1 2025 Earnings Call Transcript - Insider Monkey

May 08, 2025
pulisher
May 08, 2025

PTCT: Barclays Reduces Price Target for PTC Therapeutics | PTCT Stock News - GuruFocus

May 08, 2025
pulisher
May 08, 2025

Blackstone Inc. Cuts Holdings in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat

May 08, 2025
pulisher
May 08, 2025

uniQure: A Buy For Their Lead In Huntington's Program, In Light Of PTC's Data - Seeking Alpha

May 08, 2025
pulisher
May 08, 2025

PTC Therapeutics projects $650M to $800M revenue for 2025 amid global SUFIANCE launch preparations - MSN

May 08, 2025
pulisher
May 08, 2025

Schonfeld Strategic Advisors LLC Has $5.52 Million Position in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat

May 08, 2025
pulisher
May 08, 2025

PTC Therapeutics: Q1 Earnings Snapshot - Norwalk Hour

May 08, 2025
pulisher
May 08, 2025

Price T Rowe Associates Inc. MD Cuts Stock Holdings in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat

May 08, 2025
pulisher
May 07, 2025

PTCT: Baird Adjusts Price Target for PTC Therapeutics | PTCT Stock News - GuruFocus

May 07, 2025
pulisher
May 07, 2025

PTCT Analyst Raises Price Target Amid Outperform Rating | PTCT Stock News - GuruFocus

May 07, 2025
pulisher
May 07, 2025

PTC Therapeutics (NASDAQ:PTCT) Shares Gap DownHere's What Happened - MarketBeat

May 07, 2025
pulisher
May 07, 2025

Earnings call transcript: PTC Therapeutics beats Q1 2025 revenue forecast By Investing.com - Investing.com UK

May 07, 2025
pulisher
May 07, 2025

PTC Therapeutics (PTCT) Target Price Adjusted by Cantor Fitzgerald | PTCT Stock News - GuruFocus

May 07, 2025
pulisher
May 07, 2025

PTC Therapeutics to Participate at Upcoming Investor Conferences - Seeking Alpha

May 07, 2025
pulisher
May 07, 2025

PTC Therapeutics, Inc. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by PTC Therapeutics, Inc. (PTCT) - ACCESS Newswire

May 07, 2025
pulisher
May 07, 2025

PTC Therapeutics (PTCT) Price Target Lowered by JP Morgan | PTCT Stock News - GuruFocus

May 07, 2025
pulisher
May 07, 2025

PTC Therapeutics upgraded by Citigroup with a new price target - Quantisnow

May 07, 2025
pulisher
May 07, 2025

PTCT Stock Target Price Adjusted by Baird Analyst | PTCT Stock News - GuruFocus

May 07, 2025
pulisher
May 07, 2025

Citigroup Upgrades PTC Therapeutics (PTCT) - Nasdaq

May 07, 2025
pulisher
May 07, 2025

This Logitech International Analyst Turns Bullish; Here Are Top 4 Upgrades For Wednesday - Benzinga

May 07, 2025
pulisher
May 07, 2025

JPMorgan Adjusts Price Target for PTC Therapeutics (PTCT) | PTCT Stock News - GuruFocus

May 07, 2025
pulisher
May 07, 2025

Citigroup Upgrades PTC Therapeutics to Neutral From Sell, Adjusts Price Target to $40 From $50 - marketscreener.com

May 07, 2025
pulisher
May 07, 2025

48,728 Shares in PTC Therapeutics, Inc. (NASDAQ:PTCT) Bought by Raymond James Financial Inc. - MarketBeat

May 07, 2025
pulisher
May 07, 2025

PTC Therapeutics Swings to Q1 Earnings, Revenue Increases - marketscreener.com

May 07, 2025
pulisher
May 07, 2025

PTC Therapeutics Inc (PTCT) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and ... - Yahoo Finance

May 07, 2025
pulisher
May 07, 2025

PTC Therapeutics Inc (PTCT) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and ... By GuruFocus - Investing.com Canada

May 07, 2025
pulisher
May 07, 2025

Decoding PTC Therapeutics Inc (PTCT): A Strategic SWOT Insight - GuruFocus

May 07, 2025
pulisher
May 06, 2025

PTC Therapeutics Reports Strong Q1 2025 Results - TipRanks

May 06, 2025
pulisher
May 06, 2025

An Investigation Has Commenced on Behalf of PTC Therapeutics, Inc. Shareholders. Contact Levi & Korsinsky to Discuss your PTCT Losses - ACCESS Newswire

May 06, 2025
pulisher
May 06, 2025

PTC Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results - Citizen Tribune

May 06, 2025
pulisher
May 06, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc.PTCT - PR Newswire

May 06, 2025

Ptc Therapeutics Inc Stock (PTCT) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$65.08
price down icon 0.84%
$19.36
price down icon 0.31%
$33.15
price up icon 0.15%
$23.96
price down icon 2.80%
$92.77
price down icon 2.12%
biotechnology ONC
$231.99
price down icon 1.67%
Cap:     |  Volume (24h):